Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Charlotte Knights"'
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2109b65c80b64c5dc8e0c07cc7793822
https://doi.org/10.1158/0008-5472.c.6508109
https://doi.org/10.1158/0008-5472.c.6508109
Autor:
Mark J. O'Connor, Alan Lau, Keith W. Caldecott, Niall M.B. Martin, David Rudge, Jos Jonkers, Sven Rottenberg, Marina Pajic, Robert H. Bradbury, Attilla Ting, Bastiaan Evers, Charlotte Knights, Louise Jones, Janneke E. Jaspers, Henry Brown, Rajesh Odedra, Aaron N. Cranston, Stuart L. Rulten, Lenka Oplustil O'Connor
Supplementary materials and methods. Suppl Table 1. MMS combination PF50 cell line assays. Concentration-dependent potentiation of MMS (PF50 ratios). Suppl Table 2. Permeability of AZD2461 and olaparib were assessed. Suppl Table 3. Activity of olapar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::730097b7c140c8178ff65dd44a170b76
https://doi.org/10.1158/0008-5472.22410926.v1
https://doi.org/10.1158/0008-5472.22410926.v1
Autor:
Niall M. B. Martin, Bastiaan Evers, Charlotte Knights, Janneke E. Jaspers, Jos Jonkers, Attilla Ting, Henry Brown, Keith W. Caldecott, Sven Rottenberg, Rajesh Odedra, Lenka Oplustil O'Connor, Robert Hugh Bradbury, Aaron Cranston, David Alan Rudge, Mark J. O'Connor, Marina Pajic, Louise J. Jones, Alan Lau, Stuart L. Rulten
Publikováno v:
Cancer Research. 76:6084-6094
The PARP inhibitor AZD2461 was developed as a next-generation agent following olaparib, the first PARP inhibitor approved for cancer therapy. In BRCA1-deficient mouse models, olaparib resistance predominantly involves overexpression of P-glycoprotein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::318c6f6c6cc972443af48c50dbf1283f
https://doi.org/10.1158/0008-5472.can-15-3240
https://doi.org/10.1158/0008-5472.can-15-3240
Autor:
Xavier Jacq, Martin Stockley, Karl Richard Gibson, Charlotte Knights, Jennifer Ward, Lauren McLellan, Jeanine A. Harrigan, Gavin A. Whitlock, Edward W. Tate
Deubiquitinating enzymes play an important role in a plethora of therapeutically relevant processes and are emerging as pioneering drug targets. Herein, we present a novel probe, Ubiquitin Specific Protease (USP) inhibitor, alongside an alkyne-tagged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d98c10d4d8599a2af2f3c449a4c023f
http://hdl.handle.net/10044/1/43848
http://hdl.handle.net/10044/1/43848
Autor:
Xiao-Ling Fan Cockcroft, Graeme C. M. Smith, Marc Geoffrey Hummersone, David R. Newell, Mark Frigerio, Heather Mary Ellen Duggan, Olivier Barbeau, Christine Bailey, Nicola J. Curtin, Bernard T. Golding, Ian R. Hardcastle, Caroline Richardson, Charlotte Knights, Roger J. Griffin, Ben Spittle, Celine Cano, Keith Allan Menear
Publikováno v:
Journal of medicinal chemistry. 53(24)
Following the discovery of dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-one (NU7441) ( Leahy , J. J. J. ; Golding , B. T. ; Griffin , R. J. ; Hardcastle , I. R. ; Richardson , C. ; Rigoreau , L. ; Smith , G. C. M. Bioorg. Med. Chem. Lett. 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7234ff7d985a1c75601a34997f10fc05
https://pubmed.ncbi.nlm.nih.gov/21080722
https://pubmed.ncbi.nlm.nih.gov/21080722
Autor:
Xavier Jacq, Niall M. B. Martin, Stephen P. Jackson, Helen Robinson, Lisa Smith, Aaron Cranston, Yaara Ofir-Rosenfeld, Charlotte Knights, Jeanine A. Harrigan, Kemp Mark Ian
Publikováno v:
Cancer Research. 75:1728-1728
Ubiquitin proteasome pathways are emerging as a growing source for novel anti-cancer therapeutics. In this respect, by depleting a number of deubiquitylating enzymes (DUBs) through a combination of synthetic lethality screens and isogenic cell line m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20e2465ebcfedccbd255f4be29a3595c
https://doi.org/10.1158/1538-7445.am2015-1728
https://doi.org/10.1158/1538-7445.am2015-1728
Autor:
Krystyna J. Dillon, Niall M. B. Martin, Ian Hickson, Andrew Tutt, Manuela Santarosa, Tobias B. Richardson, Damian A. Johnson, Charlotte Knights, Christopher J. Lord, Stephen P. Jackson, Hannah Farmer, Graeme C. M. Smith, Alan Ashworth, Nuala McCabe
Publikováno v:
Nature. 434(7035)
BRCA1 and BRCA2 are important for DNA double-strand break repair by homologous recombination, and mutations in these genes predispose to breast and other cancers. Poly(ADP-ribose) polymerase (PARP) is an enzyme involved in base excision repair, a key
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee06b6ca50e45facde45f861c48a8947
https://pubmed.ncbi.nlm.nih.gov/15829967
https://pubmed.ncbi.nlm.nih.gov/15829967
Autor:
James Carmichael, Richard S. Finn, Dennis J. Slamon, Aisling O'Shaughnessy, Mark J. O'Connor, Dylan Conklin, Charlotte Knights, Ondrej Kalous, Lucy Riches, A. Lau
Publikováno v:
European Journal of Cancer Supplements. 6:175-176
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cf80da39a5603020f01a17c79a616181
https://doi.org/10.1016/s1359-6349(08)72491-1
https://doi.org/10.1016/s1359-6349(08)72491-1
Autor:
Helen Wombwell, Seock-Ah Im, Hyung-Seok Hur, Tae-You Kim, Young-Kwang Yoon, Do-Youn Oh, Sang Hyun Song, Mark J. O'Connor, Sae-Won Han, Lucy Riches, Ahrum Min, Yung-Jue Bang, Yi Gu, Charlotte Knights, Alan Lau
Publikováno v:
Cancer Research. 70:1775-1775
Background Poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP)is the member of a family of enzymes that catalyze the addition of ADP-ribose units to proteins that mediate DNA repair pathways. Olaparib (KU-0059436; AZD2281) is a potent oral inh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7c8bd7710086a4b787d4dff96159eac
https://doi.org/10.1158/1538-7445.am10-1775
https://doi.org/10.1158/1538-7445.am10-1775
Autor:
Tim French, Louise Unwin, Lucy Riches, Mark J. O'Connor, Jonathan R. Dry, Simon Dearden, Chris Harbron, Sarah Runswick, John E. Prime, Darren Hodgson, Charlotte Knights, Alan Lau, Aisling O'Shaughnessy, Helen Brown, Rama Mangena, Tim Avis
Publikováno v:
Cancer Research. 70:3497-3497
Background: Early results from Phase II trials have shown that treatment with the PARP inhibitor olaparib (AZD2281, KU-0059436) can induce tumour specific synthetic lethality in patients with BRCA-mutated breast and ovarian cancer, with little effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ce0f974f76e569f78f7fdd72f936581
https://doi.org/10.1158/1538-7445.am10-3497
https://doi.org/10.1158/1538-7445.am10-3497